GlassScriptPhysician profile
Krishnamani Chinnasamy
NPI 1497150114
$1,599.38
in general payments reported to CMS, 2019-2025
24 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2021: $73.17 · 2023: $275 · 2024: $741 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $306.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $304.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $265.31 | 2021-2024 | Qulipta |
| Amgen INC. | $104.79 | 2019 | |
| Pfizer INC. | $88.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $59.36 | 2019-2024 | Airsupra |
| Merck Sharp & Dohme LLC | $52.89 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.33 | 2023-2024 | |
| Mylan Specialty L.P. | $44.15 | 2024 | Yupelri |
| Genentech USA, INC. | $43.49 | 2019 | |
| Shield Therapeutics INC | $35.23 | 2024-2025 | |
| Astellas Pharma US INC | $31.10 | 2023-2024 | Veozah |
| Lundbeck LLC | $27.95 | 2025 | Vyepti |
| Tactile Systems Technology INC | $24.56 | 2024 | Entre Plus, Flexitouch Plus |
| Virtus Pharmaceuticals LLC | $21.03 | 2024 | Levorphanol Tartrate |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.89 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $18.29 | 2024 | Quviviq |
| Glaxosmithkline, LLC. | $16.92 | 2023 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.80 | 2021 | |
| Esperion Therapeutics, INC. | $15.82 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $15.35 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.89 | 2023 | Belbuca |
| Sanofi-Aventis U.S. LLC | $13.04 | 2019 | |
| Eisai INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnamani Chinnasamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.